ATE320793T1 - Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält - Google Patents

Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält

Info

Publication number
ATE320793T1
ATE320793T1 AT01927472T AT01927472T ATE320793T1 AT E320793 T1 ATE320793 T1 AT E320793T1 AT 01927472 T AT01927472 T AT 01927472T AT 01927472 T AT01927472 T AT 01927472T AT E320793 T1 ATE320793 T1 AT E320793T1
Authority
AT
Austria
Prior art keywords
administration
compound containing
thiol
chemoprotectant agent
intra
Prior art date
Application number
AT01927472T
Other languages
English (en)
Inventor
Michael A Pagel
Leslie Muldoon
Edward A Neuwelt
Original Assignee
Univ Oregon Health Sciences
Us Of America Through The Dept
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health Sciences, Us Of America Through The Dept filed Critical Univ Oregon Health Sciences
Application granted granted Critical
Publication of ATE320793T1 publication Critical patent/ATE320793T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT01927472T 2000-04-26 2001-04-26 Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält ATE320793T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19993600P 2000-04-26 2000-04-26
US22987000P 2000-08-30 2000-08-30

Publications (1)

Publication Number Publication Date
ATE320793T1 true ATE320793T1 (de) 2006-04-15

Family

ID=26895307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927472T ATE320793T1 (de) 2000-04-26 2001-04-26 Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält

Country Status (13)

Country Link
US (6) US7022315B2 (de)
EP (1) EP1328253B1 (de)
JP (1) JP5242877B2 (de)
KR (1) KR20030014208A (de)
CN (1) CN1443064A (de)
AT (1) ATE320793T1 (de)
AU (2) AU2001253919B2 (de)
BR (1) BR0110403A (de)
CA (1) CA2406081C (de)
DE (1) DE60118172T2 (de)
ES (1) ES2261399T3 (de)
IL (1) IL152433A0 (de)
WO (1) WO2001080832A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5242877B2 (ja) 2000-04-26 2013-07-24 オレゴン ヘルス アンド サイエンス ユニバーシティー チオールをベースとする化学保護剤の投与
EP1609468A3 (de) * 2000-11-22 2006-01-25 Rxkinetix, Inc. Eine Zusammensetzung auf der Basis eines Schwefel enthaltenden Antioxidans wie dessen Verwendung zur Herstellung eines Medikaments für die Behandlung von Mucositis
US20040062764A1 (en) * 2001-08-30 2004-04-01 Neuwelt Edward A Chemoprotectant for gastric toxicity
WO2003045334A2 (en) 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
US6815434B2 (en) 2002-01-04 2004-11-09 Sound Pharmaceuticals Incorporated Methods for treating hearing loss
WO2003057012A2 (en) * 2002-01-07 2003-07-17 Board Of Regents, The University Of Texas System S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
US20030235571A1 (en) * 2002-06-19 2003-12-25 Gabriel Gojon-Romanillos Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
US6669929B1 (en) 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US20040229815A1 (en) 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US20040198841A1 (en) * 2003-03-13 2004-10-07 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
US20050118261A1 (en) * 2003-06-12 2005-06-02 Oien Hal J. Compositions and methods of administering doxepin to mucosal tissue
TW201440760A (zh) * 2004-07-16 2014-11-01 Texas A & M Univ Sys 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物
US20070148154A1 (en) * 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US7968738B2 (en) 2005-07-29 2011-06-28 Ziopharm Oncology, Inc. Compounds and methods for the treatment of cancer
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
WO2008021550A2 (en) * 2006-08-16 2008-02-21 Oregon Health & Science University Thiol-based agents for reducing toxicities associated with medical procedures employing radiographic contrast agents
TW200829261A (en) * 2006-09-29 2008-07-16 Ziopharm Oncology Inc Method for controlling angiogenesis in animals
US20100266501A1 (en) * 2006-11-07 2010-10-21 University Of Vermont and State Agricltural College Methods and compositions for organ protection
ES2392737T3 (es) * 2007-11-02 2012-12-13 Ziopharm Oncology, Inc. Terapia combinada con compuestos arsenicales orgánicos
BRPI0821002A2 (pt) * 2007-12-12 2015-06-16 Ziopharm Oncology Inc Compostos e métodos para o tratamento de câncer
US8227517B2 (en) * 2008-02-12 2012-07-24 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
DK3388111T3 (da) 2008-08-20 2021-12-06 Solasia Pharma K K Organoarsenforbindelse til behandlingen af kræft
US20100183748A1 (en) * 2009-01-21 2010-07-22 Ikaria, Inc. Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury
CA2767168C (en) 2009-07-08 2019-04-09 Hope Medical Enterprises, Inc. D.B.A. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
CN105392478A (zh) * 2013-07-31 2016-03-09 味之素株式会社 癌症化学疗法时的副作用降低剂
AU2015259362B2 (en) 2014-05-12 2018-02-15 The Johns Hopkins University Engineering synthetic brain penetrating gene vectors
US11173135B2 (en) 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
JP7416622B2 (ja) 2017-03-08 2024-01-17 ホープ メディカル エンタープライズ インコーポレイテッド ディー．ビー．エー． ホープ ファーマシューティカルズ チオ硫酸ナトリウムの透析中の使用
EP3684418A4 (de) * 2017-09-20 2021-06-16 Thiogenesis Therapeutics, Inc. Verfahren zur behandlung von cysteaminempfindlichen erkrankungen
US10596190B2 (en) * 2017-11-29 2020-03-24 Oregon Health & Science University Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
AU2019218232A1 (en) 2018-02-09 2020-09-24 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
AU2019299216A1 (en) 2018-07-03 2021-01-07 Fennec Pharmaceuticals, Inc. Anhydrous sodium thiosulfate and formulations thereof
WO2020140029A1 (en) * 2018-12-27 2020-07-02 Montefiore Medical Center Nucleophilic chemicals useful in the treatment of cisplatin-induced sensory neuropathy and ototoxicity
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
FR3099051A1 (fr) * 2019-07-25 2021-01-29 Laboratoires Grimberg Composition pour pulvérisation nasale ou buccale contenant du soufre
EP4090238A4 (de) * 2020-01-16 2024-04-10 The United States of America, as represented by the Secretary, Department of Health and Human Services Echtzeit-überwachung von freien radikalfängern in vivo durch hyperpolarisierte n-acetyl-cystein-isotope
CN114848836B (zh) * 2021-07-06 2023-09-15 中山大学孙逸仙纪念医院 一种偶联物及其在治疗内耳疾病上的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474759A (en) * 1982-07-22 1984-10-02 Vojislav Petrovich Method of treating bacterial, viral or parasitic diseases
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
WO1992008448A1 (en) 1990-11-09 1992-05-29 Cell Technology, Inc. Method for preventing drug-induced or radiation myelosuppression
IT1258781B (it) * 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
US5618823A (en) 1992-06-24 1997-04-08 Boehringer Mannheim Italia S.P.A. Glutathione as chemoprotective agent
US5424471A (en) 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
DE4228455A1 (de) * 1992-08-26 1994-09-15 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5843481A (en) * 1994-01-18 1998-12-01 Mount Sinai Hospital Corporation Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5846958A (en) 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US5643853A (en) 1995-02-28 1997-07-01 Purdue Research Foundation Thiol activation of cytotoxic and auxin-herbicidal agents and root formation stimulation
US6110891A (en) * 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
ES2170414T3 (es) 1996-09-23 2002-08-01 Bionumerik Pharmaceuticals Inc Reduccion de efectos toxicos del carboplatino usando ditioeteres.
US6573253B2 (en) 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
JP5242877B2 (ja) 2000-04-26 2013-07-24 オレゴン ヘルス アンド サイエンス ユニバーシティー チオールをベースとする化学保護剤の投与
US6759061B2 (en) * 2001-08-31 2004-07-06 Renew Life, Inc. Liver function improvement formulation
WO2003045334A2 (en) 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
WO2004039336A2 (en) 2002-10-31 2004-05-13 Oregon Health & Science University Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia

Also Published As

Publication number Publication date
US20170182089A1 (en) 2017-06-29
WO2001080832A2 (en) 2001-11-01
EP1328253A2 (de) 2003-07-23
CN1443064A (zh) 2003-09-17
US20030176359A1 (en) 2003-09-18
US20160184353A1 (en) 2016-06-30
DE60118172D1 (de) 2006-05-11
DE60118172T2 (de) 2007-03-08
JP2003531164A (ja) 2003-10-21
US20060177523A1 (en) 2006-08-10
CA2406081C (en) 2009-12-22
EP1328253B1 (de) 2006-03-22
AU5391901A (en) 2001-11-07
JP5242877B2 (ja) 2013-07-24
AU2001253919B2 (en) 2006-12-14
ES2261399T3 (es) 2006-11-16
US20180289737A1 (en) 2018-10-11
US7022315B2 (en) 2006-04-04
WO2001080832A3 (en) 2003-05-15
CA2406081A1 (en) 2001-11-01
KR20030014208A (ko) 2003-02-15
IL152433A0 (en) 2003-05-29
BR0110403A (pt) 2004-02-25
US20200000844A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
ATE320793T1 (de) Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
WO2000041726A3 (en) Noninvasive vascular therapy
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BR0014525A (pt) Processo de tratamento de distúrbios metabólicos, especialmente diabetes, ou uma doença ou condição associada com diabetes
NO993393D0 (no) Fotokjemoterapeutiske blandinger
MX9302038A (es) Metodo para el tratamiento del cancer por una terapia conjunta con derivados de 2-halometilideno y un agente antineoplasico especifico de fase m o fase s.
BRPI0517953A (pt) uso de zd 6474, ou de um sal farmaceuticamente aceitável do mesmo, e de um antiandrógeno, composição farmacêutica, kit, e, método para a produção de um efeito da redução da permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente
AR011133A1 (es) MICROGRÁNULOS DE LIBERACIoN CONTROLADA QUE CONTIENEN CISPLATINO , PROCEDIMIENTO DE SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA Y UTILIZACIoN EN LA FABRICACIoN DE UN MEDICAMENTO POLIQUIMIOTERAPIA O EN ASOCIACIoN CON UNA RADIOTERAPIA.
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
BR0313117A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como um humano, composição farmacêutica, kit, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável e de zd1839 ou de um seu sal farmaceuticamente aceitável
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
IL140848A0 (en) Treatment regimen for administration of phenylacetylacetylglutamine, phenylacetylisoglutamine and/or phenylacetate
SE7612534L (sv) Forfarande for framstellning av farmaceutiska preparat for behandling av storningar i kalciumemnesomsettning
SE8602743L (sv) Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid
BR9814419A (pt) "combinação de compostos de benzociclo-heptapiridina e drogas antineopláticas para tratamento de doenças proliferativas"
DE69835435D1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
BR0110150A (pt) Método e composição para o tratamento de câncer por meio da administração de agentes quimioterápicos indutores da apoptose
Cheli et al. Photodynamic therapy of spontaneous animal tumors using the active component of hematoporphyrin derivative (DHE) as photosensitizing drug: Clincal results
Kaplan et al. Mitomycin and fluorouracil with concomitant radiotherapy in head and neck cancer
KR927002224A (ko) 항종양효과증강제 및 항종양제
GB2356347B (en) Pharmaceutical compositions and their use
ID28035A (id) Kegunaan turunan antrasiklin untuk pengobatan tumor hati

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties